FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed ...

Summary of Sharps Technology (STSS) Conference Call Company Overview - **Company Name**: Sharps Technology - **Ticker Symbol**: STSS - **Industry**: Drug delivery and medical devices, specializing in smart safety syringes and prefillable syringes - **Founded**: 2017, IPO completed in 2022 [4][2] Key Points and Arguments Business Developments - **Sales Agreement**: Signed a $50 million agreement to supply SoloGuard products to a U.S. drug filler, with initial shipments starting this quarter [7][24] - **Funding**: Successfully raised $20 million to expand the European facility to support the sales agreement [8][51] - **Product Commercialization**: Successfully commercialized three products: SoloGuard, SecurGuard, and a syringe for auto injectors [8][9] Facilities - **European Facility**: - Located in Hungary, fully operational with no debt [10][11] - 40,000 to 45,000 square feet, expandable for future sales agreements [11] - **South Carolina Facility**: - Under negotiation for acquisition, 100,000 square feet, specialized for prefilled syringes [12][21] Product Lines - **Smart Safety Syringes**: Focus on low waste and reuse prevention technologies [16][29] - **Prefilled Syringes**: High-value products with significant revenue potential, transitioning from glass to copolymer materials for better manufacturing efficiency [17][23][29] Market Dynamics - **Growth Potential**: The syringe market, particularly disposable and prefilled syringes, is one of the fastest-growing segments in healthcare [27][30] - **Pricing**: Prefilled syringes priced between $1.50 to $6, compared to standard syringes priced at $0.10 to $0.50 [29][53] - **Demand for Injectable Filling Capacity**: Major pharmaceutical companies are investing heavily in filling technology, indicating strong market demand [35] Financial Health - **Debt-Free Status**: The company has no debt and approximately $12 million in cash [10][45] - **Market Capitalization**: Estimated around $6 million [45] Future Outlook - **Production Capacity**: Expected to ramp up to 120 million to 130 million units per year starting in year two of the sales agreement [25][50] - **Expansion Plans**: Potential to grow beyond the initial sales agreement with additional purchase orders anticipated [41][52] Additional Important Information - **Regulatory Approvals**: Products are FDA approved, CE marked, and WHO approved, highlighting the regulatory compliance necessary in the healthcare sector [6] - **Team Experience**: Leadership team has extensive experience in drug manufacturing and packaging, enhancing investor confidence [36][37] - **Market Trends**: Increasing demand for GLP-1 drugs and the transition to prefilled syringes and auto injectors are expected to drive future growth [52][53] This summary encapsulates the key points discussed during the Sharps Technology conference call, providing insights into the company's operations, market position, and future growth potential.

"诚挚欢迎各位企业家朋友选择广东，投资广东，深耕广东，'赚钱多、麻烦少、身体好'，是我们不变 的承诺。"广东省商务厅副厅长朱小军在招商环节呼吁道。 6月12日，广东省政府、广东省商务厅在广州举办"日本企业广东行"活动，吸引210家日本企业参加。活 动聚焦低空经济、人工智能、汽车、生物医药与健康、商贸服务等5大产业，举办了专题对接会。 当前，广东正大力推进低空经济和人工智能的应用场景开发。广东省机器人协会执行会长任玉桐介绍， 广东拥有全球最大的机器人市场、最全的产业链和最强的制造基因，只要政策、资本、技术协同发力， 完全有能力成为全球机器人产业高地。 广东省投资促进局副局长刘德增表示，广东已形成了多个具有国际竞争力的产业集群，如电子信息产业 集群、汽车产业集群，产值均过万亿，日本企业可以融入这些产业集群，与本地企业开展合作，实现产 业链上下游的协同发展，降低生产成本，提高生产效率。 "期待广东的'智造之光'与日本的'精密之魂'相遇，书写智能制造的新篇章。"刘德增表示。 对接会上， 近60家中日企业进行了长达两小时的额"一对一"洽谈，其中6家企业达成初步合作意向。 "全国每四辆新能源汽车就有一辆产自广东" 现场还 ...

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (t ...

Core Insights - Medtronic plc announced the name "MiniMed" for its planned new Diabetes Company, honoring its legacy and 40-year history in diabetes care [1] - The company aims to enhance diabetes management through innovative technology, making it more predictable and less burdensome for patients [1][2] - The separation of the Diabetes business is targeted for completion within 18 months, subject to legal and customary conditions [3] Company Overview - Medtronic is a global leader in healthcare technology, focusing on transforming diabetes care [1] - The Diabetes business employs over 8,000 individuals dedicated to innovation and improving health outcomes for diabetes patients [2] Historical Context - MiniMed was originally founded in 1983 by Alfred E. Mann, introducing groundbreaking innovations in diabetes care [1] - The name change reflects the company's commitment to its roots and the trust built over decades [1] Future Plans - The separation will involve capital markets transactions, potentially including a spin-off or split-off of the remaining shareholding in MiniMed [5] - The company is committed to fulfilling its mission of making diabetes management more stable and predictable [1][2]

Core Insights - ReShape Lifesciences has signed an exclusive U.S. distribution agreement with Recon Supply to distribute its medical products to U.S. veterans and active-duty service members [1][2] - The partnership aims to enhance access to innovative medical technologies, including the STIMEL-03 neuromuscular rehabilitation device and the Lap-Band® 2.0 FLEX [2] - Recon Supply has experienced significant growth, with a 113% year-over-year increase since its relaunch in 2022, and now distributes to 102 VA Medical Centers nationwide [2] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of FDA-approved products for obesity management [4] - The company’s portfolio includes the Lap-Band® System, a minimally invasive treatment for obesity, and other innovative technologies aimed at treating metabolic disorders [4] - Recon Supply is a Service-Disabled Veteran-Owned Small Business (SDVOSB) focused on delivering high-quality medical solutions while supporting the veteran community [3]

Core Insights - The PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates long-term benefits of PoNS Therapy for gait deficits in individuals with Multiple Sclerosis (MS) [1][2] - The study results were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, highlighting the importance of treatment adherence for achieving clinically meaningful improvements [2][3] Study Details - The PoNSTEP study is an open-label, observational, interventional multi-center research study assessing adherence to PoNS Therapy for gait deficits in MS patients [5] - The study involved 43 MS participants and was conducted at six Centers of Excellence across the United States [5] - The primary endpoint is the maintenance of gait improvement from the end of supervised therapy to the end of unsupervised therapy, with secondary endpoints including maintenance of improvement over six months [5] Treatment and Mechanism - PoNS Therapy combines the Portable Neuromodulation Stimulator (PoNS) device with physical therapy, applied for 100-120 minutes per day [5][7] - The PoNS device delivers mild electrical impulses to the tongue and is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms [7][8] Clinical Impact and Recognition - The study provides the first clinical trial evidence of PoNS Therapy's long-term benefits for functional rehabilitation in the MS population [3] - There is growing recognition of PoNS Therapy's direct effect on the central nervous system and its targeted mechanism of action compared to other interventions [3] Reimbursement and Access - Helius Medical Technologies has successfully obtained initial reimbursement from federal and private payers, which is expected to lower barriers to prescribing PoNS Therapy [4] - The company is actively engaging with health insurance providers to expand access to PoNS Therapy for all individuals with MS [3][4]

FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase ord ...

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152569&from=4CLA ...

Nano-X Imaging (NNOX) Conference June 11, 2025 01:45 PM ET Speaker0 Welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, Ron, I'll turn it over to you. Speaker1 You, Alex, and good afternoon for everyone. Before we'll get started, I would like to remind everyone that I'll be making statements during this presentation that may be deemed forward looking statements regarding our activities, commercializat ...